Wall Street analyst estimates for Surgery Partners, Inc. (SGRY): consensus price target and buy/hold/sell recommendations.
Surgery Partners, Inc. operates a nationwide network of surgical facilities and associated medical services across the United States. Its business is categorized into two segments: Surgical Facility Services and Ancillary Services.
Consensus price target
$21.33 (-8 % vs price $23.21)
between $17.00 and $23.50 · 4 targets published in the last quarter
Closing price, Oct 30
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 13 |
| Hold | 10 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 23 |
| Avg rating (−2 sell to +2 buy) | 0.56 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-09 | $0.11 | ||
| 2026-08-10 | $0.10 | $0.06 | +72.6% |
| 2026-05-05 | $-0.03 | $-0.15 | +80.0% |
| 2026-03-02 | $0.12 | $0.31 | -61.3% |
| 2025-11-10 | $0.13 | $0.19 | -31.6% |
| 2025-08-05 | $0.17 | $0.16 | +6.3% |
| 2025-05-12 | $0.04 | $0.08 | -50.0% |
| 2025-03-03 | $0.44 | $0.38 | +15.8% |
Valuation Ratios
| Price / Book | 1.79 |
| EV / EBITDA | 7.22 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.15B | $1.34B | $1.77B | $1.83B | $1.86B | $2.23B | $2.54B | $2.74B | $3.11B | $3.31B |
| Cost of Revenue | $821.2M | $1.01B | $1.36B | $1.41B | $1.48B | $1.73B | $1.96B | $2.10B | $2.37B | $2.54B |
| Gross Profit | $324.2M | $327.4M | $410.0M | $423.8M | $379.8M | $491.4M | $574.9M | $647.5M | $745.6M | $765.0M |
| Research & Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | $60.2M | $76.0M | $93.6M | $88.6M | $97.1M | $104.0M | $102.2M | $120.9M | $138.7M | $522.7M |
| Operating Expenses | $123.7M | $156.4M | $157.2M | $187.9M | $196.8M | $189.2M | $229.7M | $319.5M | $396.8M | $375.5M |
| Operating Income | $196.5M | $158.2M | $77.8M | $235.9M | $183.0M | $302.2M | $345.2M | $328.0M | $348.8M | $389.5M |
| EBITDA | $245.2M | $251.9M | $144.7M | $310.0M | $277.8M | $401.0M | $460.0M | $446.1M | $501.4M | $565.5M |
| Interest Expense | $100.6M | $117.7M | $147.0M | $178.9M | $201.8M | $221.0M | $234.9M | $193.0M | $201.7M | $272.6M |
| Pre-tax Income | $92.2M | $82.3M | -$69.2M | $54.6M | -$18.8M | $81.2M | $110.3M | $135.0M | $147.1M | $116.9M |
| Income Tax | $7.1M | $53.5M | $26.5M | $9.5M | -$20.1M | $10.5M | $23.3M | -$300,000 | $134.6M | $18.0M |
| Net Income | $9.5M | -$53.0M | -$205.7M | -$74.8M | -$116.1M | -$70.9M | -$54.6M | -$11.9M | -$168.1M | -$77.9M |
| EPS | $0.20 | $-1.09 | $-4.28 | $-2.29 | $-3.19 | $-1.12 | $-0.59 | $-0.09 | $-1.33 | $-0.61 |
| EPS (Diluted) | $0.20 | $-1.08 | $-4.28 | $-2.29 | $-3.19 | $-1.12 | $-0.59 | $-0.09 | $-1.33 | $-0.61 |
| Shares Outstanding (Diluted) | 48.2 M | 49.0 M | 48.0 M | 48.3 M | 48.8 M | 72.4 M | 92.0 M | 125.6 M | 126.1 M | 127.2 M |
Price
| Price | $23.21 (closing price, October 30, 2026) |
| Market Cap | $3.0B |
| Exchange | NASDAQ |
| Country | US |
Related companies: HCA · THC · UHS · 0J1R.L · 0RPS.L · EHC · DVA · FMS
Explore sector: Healthcare · Medical - Care Facilities
More sections of SGRY: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks